BioDue
On 18 May 2015 BioDue S.p.A. obtained the admission of the shares to the AIM Italia market organized and managed by Borsa Italiana. The start of negotiations took place on 20 May 2015.
Integræ SIM acted as the Global Coordinator of the private placement and is currently a Specialist of the Issuer. The total amount of the collection in the IPO was approximately Euro 4 million entirely in a capital increase.
The placement price is equal to € 3.55. On the first negotiating day, the security recorded a closing price of Euro 4.82 with a +35.77% increase compared to the Placement Price.
The enterprise. BioDue develops, manufactures, and markets medical devices, dermo-cosmetic products, and food supplements (solids and liquids) with a particular focus on phytotherapeutic preparations. The company operates both on behalf of large national and international pharmaceutical companies (“Industrial Division”) and for its brands (“Pharcos, Selerbe, and Biofta Divisions” dermatological, phytotherapeutic, and ophthalmic products).
Ultima Ricerca BioDue
UPDATE| Borgosesia reported results in line with the Business Plan, confirming a stable operating model and high profitability. Consolidated revenues amounted to €14.43 million, supported by real estate sales and income from repossession strategy receivables. Gross operating profit stood at €9.61 million, undergoing physiological normalization but still accounting for more than 50.0% of revenues, while EBITDA amounted to €7.29 million (margin of 52.5%) with net income of €2.08 million. On the strategic front, tangible progress has been made: the growth in AUM to €133.00 million (compared to €79.00 million at December 31, 2024) confirms the progress of the third-party management model, despite a natural phase of building fundraising capacity in a highly competitive market. Finally, disposals and collections during the period contributed to the improvement in Adj. NFP to €85.02 million, freeing up resources and strengthening the financial structure. Overall, the half-year shows concrete progress in the transformation process and lays a solid foundation for the expansion of recurring and asset-light activities. Considering the performance in the first half of the year and the Company’s recent announcements, we see no reason to update the forecasts made in the previous report. We expect FY25E production value to be €25.50 million with EBITDA of €12.50 million, corresponding to a margin of 49.0%, and growth in production value to €32.7 million (CAGR 24A-27E: 10.1%) in FY27E, with EBITDA of €19.00 million and a margin of 58.1%. We confirm our target price of €2.50, BUY rating, and MEDIUM risk. |
